leadf
logo-loader
viewMydecine Innovations Group Inc
(
OTC:MYCOFFRA:0NFANEO:MYCO
)

Mydecine Innovations Group: Initiation report

Mydecine Innovations Group is a biotech and life sciences company developing and commercializing new therapies for mental health and other conditions. The company has three lines of activity – pharmaceutical drug development, natural health products, and the Mindleap digital health platform.

We believe that the drug development pipeline represents the biggest value driver for the stock price over the next two years, and in this report we focus in particular on two therapies that are undergoing Phase II clinical trials. Both of these use Mydecine’s proprietary formulation MYCO-001, which is a purified form of psilocybin, a psychedelic compound found in mushrooms sometimes referred to as ‘magic mushrooms’.

The first clinical trial subject is a novel therapy for post-traumatic stress disorder (PTSD). This addresses a market of around US$1bn annually, and potentially greater if a new treatment proves more effective than existing drugs. Trials are being conducted at locations in Canada, the USA, and Europe. The program is also being conducted in collaboration with military veterans' organisations, and this partnership is a unique differentiator for Mydecine.

The other trial program is pursuing a nicotine addiction therapy, also using MYCO-001. This addresses a global market of around US$20bn, increasing to US$50bn if the same treatment is applied to other addictions which could be addressed going forward. We believe that this program could advance to Phase II / III trials during H2 2021.

Importantly, Mydecine has in place a compelling strategy for ring-fencing intellectual property (IP). This is one of the main challenges in psychedelic medicine as drugs are being derived from compounds that have been known to science for decades. In this report, we examine Mydecine’s position in the emerging psychedelic medicine space, its drug pipeline, and its IP strategy.

 

Quick facts: Mydecine Innovations Group Inc

Follow
OTC:MYCOF

Price: 0.27 USD

Market Cap: $64.45 m

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Mydecine Innovations Group outlines plan for MYCO-001 Phase 2/3 Smoking...

Mydecine Innovations Group Inc (OTC:MYCOF, FRA:0NFA, NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) (NEO:MYCO) CEO Joshua Bartch tells Proactive it has partnered with Principal Investigator Dr Matthew Johnson of Johns Hopkins University on a study evaluating the administration of its lead drug candidate...

2 weeks, 1 day ago

24 min read